Willing to Win

Christian Rados

Biotech Leaders Against All Odds Biotech leaders, founders and executives are warriors chasing cures against impossible odds. Their journeys are not only about science, but about belief, resilience, and leadership. Willing to Win is the podcast where these stories are told - the late nights, the rejections, the doubts, and the unshakable conviction that keeps them going. Each episode gives listeners an intimate look into the emotional “why” behind biotech leaders, offering inspiration, connection, and lessons in leadership and perseverance that apply far beyond biotech.

Folgen

  1. Every Chapter Needs a Different You - The Cost of Not Transforming (Peter Seufer-Wasserthal)

    19. MÄRZ

    Every Chapter Needs a Different You - The Cost of Not Transforming (Peter Seufer-Wasserthal)

    Episode 8 of Willing To Win Every Chapter Needs a Different You - The Cost of Not Transforming with Peter Seufer-Wasserthal   Peter Seufer - Wasserthal didn't have one career. He had eight. Each chapter demanded a version of himself that didn't exist yet.   PhD chemist. Business developer. Remote operator from anAustrian village before the internet. The outsider who outperformed the insider. The guy who trained four bosses before becoming one himself. Interim CEO who fell overboard. And finally, the startup mentor he waited fifteen years too long to become.   Peter is Chairman of the Board at Imperagen and PlanetSmart. Over thirty years he led business development and commercial strategy across Chemie Linz, Altus Pharmaceuticals, Evotec, Morphochem, Codexis,Intrexon, Origenis, Sestina Bio, and Willow Biosciences, where he served as President and CEO.   In this conversation, Christian Rados speaks to Peter Seufer- Wasserthal about what nobody tells you about identity shifts in biotech.  Topics covered:  - Why scientists who move to business aren't failedscientists - What it actually takes to lead without positionalauthority across time zones and cultures - The moment your words change meaning because you becamethe boss - Why your company sees the person who walked in on day one,not who you've become - The one question every founder needs to answer: do youwant to be king, or do you want to be rich? - Why hiring people who aren't better than you builds akingdom with no clothes on - The five-minute leadership diagnostic that reveals whetheryour calendar matches your strategy - What fifteen years of knowing you should change and notdaring to actually costs - Why the sailing principle of reefing your sails is themost honest decision framework for career transitions   If you're standing between who you've been and who you needto become, this is the episode.   New episodes featuring leaders from biotech, pharma, and high-stakes decision-making. Connect with Peter Seufer - WasserthalLinkedIn: https://www.linkedin.com/in/peter-seuferwasserthal-97b3102 Connect with Christian RadosLinkedIn: https://www.linkedin.com/in/christianrados-biotechdreamteams/ or rados-recruiting.com If you have ever outgrown a role and wondered whether it was time to leave - or watched yourself train the person who became your boss - or sat in a chapter you knew was ending but couldn't bring yourself to close - this episode is the mirror you didn't know you needed.

    36 Min.
  2. How The Biotech Game Breaks Your Idealism - A Drug Hunter's Confession (Zoltan Magyarics)

    12. MÄRZ

    How The Biotech Game Breaks Your Idealism - A Drug Hunter's Confession (Zoltan Magyarics)

    Willing to Win - Biotech Leaders Against All Odds Episode 7 Every scientist who enters drug development believes the science will find its way. That if the biology is right, the path forward is clear. That conviction is enough. Zoltan Magyarics believed it too. Then the phase two failed. The lead program died. And the belief that great science finds its own way broke with it. In this episode of Willing To Win, Christian Rados sits down with Zoltan Magyarics, physician, PhD immunologist, and VP of R&D at AOP Health. Over 15 years and four companies Arsanis, Bloom Diagnostics, Leyden Labs, and AOP Health - Zoltan has been inside the room when the money runs out, when the program collapses, and when the romantic idea of what science is worth collides with the financial reality of what you can actually afford to do. This is the confession the industry has in private but never on record. The study design wasn't chosen because it was right. It was chosen because it was the only one they could afford. The decision that looked like strategy was a decision that made itself. And in European biotech culture, when it goes wrong, you don't get called experienced. You get called a fallen angel. Zoltan has watched brilliant founders fail not because they were wrong about the science - but because they never understood who would pay for the drug, never built real optionality, and never admitted out loud what was actually driving their decisions. In this episode, Zoltan breaks down: Why most biotechs are functionally one-trick ponies - even with a full portfolioThe finance-driven study design decision nobody openly admits is happeningWhat early-stage founders systematically misunderstand about payers and commercial endpointsWhy the decision that feels like strategy is often a decision that made itselfWhat failure across Arsanis, Bloom Diagnostics, Leyden Labs, and AOP Health actually taught him about surviving the gameWhy European biotech culture punishes failure - and why that has to changeThe one piece of advice every early-stage founder needs to hear before they design their next studyThis is not a success story. It is a forensic look at how idealism dies inside the biotech machine - and what the people who survive it had to unlearn to keep going. 🎧 Listen and FollowAccess the full episode on all platforms:👉 https://linktr.ee/willingtowinpodcast 🔔 Subscribe to Willing To WinConversations with biotech founders, CMOs, and drug developers who have operated across every side of the table. No highlight reels. No pitch deck versions.👉 / @willingtowinpodcast New episodes every week featuring leaders from biotech, pharma, and high-stakes decision-making. Connect with Zoltan Magyaricshttps://www.linkedin.com/in/zoltan-magyarics-ba2163174/ Connect with Christian Radoshttps://www.linkedin.com/in/christianrados-biotechdreamteams/ www.rados-recruiting.com If you have ever watched a great program fail for reasons that had nothing to do with the science - or suspected that the model itself might be broken — this episode is the conversation you have been waiting for someone to have out loud. #biotech #pharma #drugdevelopment #leadership #startup #entrepreneurship #venturecapital #CEO #founder #clinicaldevelopment #AOPHealth #LeydenLabs #BloomDiagnostics #Arsanis #willingtowin #lifesciences #biopharma #raredisease #healthtech #innovation

    30 Min.
  3. What Nobody Tells You About a Life-Changing Deal (Erich Tauber)

    5. MÄRZ

    What Nobody Tells You About a Life-Changing Deal (Erich Tauber)

    What Nobody Tells You About a Life-Changing Deal (Erich Tauber) Episode 6 13 years of building. Never funded for more than 12 months. Hundreds of investors who said this will never work. Then a life-changing deal with Merck, signed in the middle of a pandemic, thirty minutes after telling the notary it was fifty-fifty. But the hardest part wasn't the struggle. It was what came after. In this episode of Willing To Win, Christian Rados sits down with Erich Tauber, co-founder and former CEO of Themis Bioscience, the Vienna-based vaccine company built on a platform nobody cared about until COVID made the world pay attention. Before founding Themis, Erich trained as a paediatrician and held roles at AstraZeneca, Baxter, Intercell, and Nycomed. He now works as a venture partner and advisor to early-stage biotech founders navigating the same journey he survived. This conversation confronts what most founder stories leave out. Not the highlight reel, the cost. The identity shift required to keep going when the evidence says stop. And the silence that follows when you finally win. In this episode, Erich explains: - Why eliminating Plan B was his greatest strategic decision - How being outfunded ten to one forced a discipline that became his edge - The moment VCs told him to talk about cancer, three weeks before COVID - Why part-time founders signal distrust to everyone around them - The post-deal crisis nobody warns you about- What he tells young founders about getting fully exposed This is not a success story. This is a conversation about what conviction costs. Before, during, and after the win. 🎧 Listen and FollowAccess the full episode on all platforms:👉 https://linktr.ee/willingtowinpodcast 🔔 Subscribe to Willing To WinIf you value conversations with biotech founders, CEOs, and leaders who built against the odds, subscribe here:👉 https://www.youtube.com/@willingtowinpodcast?sub_confirmation=1 New episodes featuring leaders from biotech, pharma, and high-stakes decision-making. Connect with Erich TauberLinkedIn: https://www.linkedin.com/in/erich-tauber-0ba8a111/ Connect with Christian RadosLinkedIn: https://www.linkedin.com/in/christianrados-biotechdreamteams/www.rados-recruiting.com If you've ever kept going when nobody believed in what you were building, or wondered what happens when they finally do, this episode is for you.

    38 Min.
  4. Winning The Infinite Game - Why Great Leadesr Embrace Failure (Ilkka Haukijärvi)

    26. FEB.

    Winning The Infinite Game - Why Great Leadesr Embrace Failure (Ilkka Haukijärvi)

    If you take real risks as a leader, failure is guaranteed. The only question is when. Most executives try to avoid failure. Great leaders prepare for it. In Episode 5 of Willing To Win Biotech Leaders Against All Odds, Christian Rados sits down with Ilkka Haukijärvi to explore what Winning means. Ilkka made a radical domain jump. From Director of HR at a Finnish university to CEO building a global vaccine CRO from scratch.No inherited credibility.No industry safety net. One of the most regulated, high stakes industries in Europe. Six months later, the organization was fully operational. This conversation is not about career progression.It is about identity under pressure. Because bold leadership requires vulnerability. And vulnerability means exposure. In this episode, Ilkka shares: • Why saying yes before you feel ready changes your trajectory • The hidden psychological cost of domain jumps• Why failure is inevitable in leadership • How energy and discipline shape executive performance• What it means to play the infinite game • How to build something that endures beyond youIf you are stepping into a bigger arena than your current title, this episode will resonate. Willing To Win is about leadership when the stakes are real. No hype. No shortcuts. Just decisions that carry consequence. 🎧 Listen and follow Access the full episode on all platforms: 👉 https://linktr.ee/willingtowinpodcast 🔔 Subscribe to Willing To Win👉 / @willingtowinpodcast New episodes featuring biotech CEOs and leaders operating under real pressure. Failure is inevitable. The question is: Are you built to endure it? Connect with Ilkka Haukijärvi LinkedIn: https://www.linkedin.com/in/ilkkahaukijarvi/ Connect with Christian Rados LinkedIn: https://www.linkedin.com/in/christianrados-biotechdreamteams/Rados Recruiting: www.rados-recruiting.com

    27 Min.
  5. Ownership Of The Downside | Elite Leaders Under Pressure (Jesper Brandgaard)

    19. FEB.

    Ownership Of The Downside | Elite Leaders Under Pressure (Jesper Brandgaard)

    Willing To Win: Biotech Leaders Against All Odds Episode 4 Ownership Of The Downside | Elite Leaders Under Pressure (Jesper Brandgaard) What separates elite leaders from the rest? In this episode of Willing To Win, Christian Rados sits down with Jesper Brandgaard to unpack a leadership principle most executives underestimate: If you want authority, you must own the downside. Jesper Brandgaard is Chairman of LEO Pharma and former CFO of Novo Nordisk, where he served for 18 years. Across decades in global pharma and nearly 30 board roles, he has operated where capital allocation, governance, and accountability carry real consequence. This conversation goes beyond theory. It begins with a simple but uncomfortable standard: “I am actually willing to accept responsibility also for things that go wrong.” Because uncertainty is part of leadership. Gambling is not. In this episode, Jesper explains: • Why most leaders fail when pressure hits • The difference between acting under uncertainty and gambling • How elite leaders evaluate acquisitions and capital allocation • Why accountability builds trust inside organizations • What stewardship really means at Chairman level • How to decide when you don’t have perfect information Willing To Win is about leadership when the stakes are real. Responsibility without applause. Judgment without certainty. Authority earned through ownership. 🎧 Listen & Follow Access the full episode on all platforms: 👉 https://linktr.ee/willingtowinpodcast If you value conversations with biotech chairmen, CEOs, and leaders operating under real pressure, subscribe to Willing To Win. New episodes featuring leaders from biotech, pharma, and high-stakes decision-making. ⸻ Connect with Jesper Brandgaard LinkedIn: https://www.linkedin.com/in/jesper-brandgaard-885ba8159/ Connect with Christian Rados LinkedIn: https://www.linkedin.com/in/christianrados-biotechdreamteams/ Website: www.rados-recruiting.com If you lead people, allocate capital, or carry board-level responsibility, this conversation will resonate. What does “owning the downside” mean in your leadership role?

    40 Min.
  6. An IPO Is Just The Beginning | The Real Fight Starts When You Go Public (Oliver Schacht)

    12. FEB.

    An IPO Is Just The Beginning | The Real Fight Starts When You Go Public (Oliver Schacht)

    Willing To Win: Biotech Leaders Against All OddsEpisode 3An IPO Is Just the Beginning | The Real Fight Starts When You Go Public (Oliver Schacht) In this episode of Willing To Win, Christian Rados sits down with Oliver Schacht to unpack a truth most founders only discover the hard way: The IPO is not the victory.It is the moment the real pressure begins. Oliver Schacht is a PhD-trained molecular biologist turned biotech CEO who has led companies through the intensity of public markets in Europe and the United States. He has raised capital across borders, navigated regulatory storms, faced investor scrutiny, and operated under the full transparency of listed companies. But this conversation is not about ringing the bell. It begins with a sentence that changes the tone immediately: “I had to cancel my honeymoon for the IPO.” Not said with pride.Said with clarity. Because markets do not reward milestones.They reward performance. Every quarter. Every signal. Every word. Oliver speaks openly about what happens after the headlines fade. The volatility. The scrutiny. The loneliness. The weight of knowing that a single sentence can move markets. This episode explores what leadership demands when you operate in full visibility. When market cycles turn against you. When uncertainty becomes constant and conviction becomes your anchor. Rather than focusing on deal mechanics, this conversation goes deeper. Into the mindset required to endure public pressure. Into the discipline of staying calm when stock prices swing. Into the resilience required to carry thousands of shareholders while protecting your team. Topics discussed include: Why an IPO marks the start of the hardest chapterThe psychological shift from private founder to public CEOThe difference between European and U.S. capital marketsLeading when every word has consequencesThe loneliness of accountability at scaleWhat it takes to stay in the game when markets turn hostile Willing To Win is about biotech leadership when the odds are real. It is about decisions made without certainty, responsibility carried without applause, and the conviction required to move forward when the stakes are public. Episode 3 guestOliver Schacht Oliver Schacht is a biotech executive and former public company CEO with deep experience across science, capital markets, and executive leadership. He has co-founded and led publicly traded life science companies, executed IPOs, raised significant international financing, and operated at the intersection of innovation and investor scrutiny. Today, he serves as CEO of Life Science Nord. His career reflects what it truly means to lead under pressure, where ambition meets accountability and resilience defines survival.

    47 Min.
  7. Feeling Out Of Place | The Story Behind Edwin Moses - And How Insecurity Fueled Optimism (Edwin Moses)

    5. FEB.

    Feeling Out Of Place | The Story Behind Edwin Moses - And How Insecurity Fueled Optimism (Edwin Moses)

    Willing To Win: Biotech Leaders Against All Odds Episode 2 Feeling Out Of Place | The Story Behind Edwin Moses - And How Insecurity Fueled Optimism In this episode of Willing to Win, Christian Rados sits down with Edwin Moses, one of the most accomplished and quietly influential leaders in European biotech, to explore the inner journey behind a lifetime of exceptional outcomes. Edwin Moses has played a defining role across decades of biotech leadership. He served as Chairman of Ablynx, which was acquired by Sanofi for €3.9 billion, and later as Chairman of Dark Blue Therapeutics, acquired by Amgen for $840 million. These are rare wins. But this conversation is not about celebrating deals or numbers. Instead, it goes back to the beginning. Long before boardrooms, transactions, or public recognition, Edwin was a child who felt deeply out of place. Insecure. Visibly different. Learning early that attention could feel unsafe and that staying unnoticed sometimes felt like the best option. Rather than disappearing, those early experiences stayed with him. Over time, they shaped a mindset grounded in humility, gratitude, and a quiet optimism. Not the loud optimism of certainty or bravado, but a steady inner belief that if you work hard, stay patient, and keep going, things will be okay. In this conversation, Edwin reflects on how insecurity does not always lead to fear or withdrawal. In some cases, it becomes fuel. Fuel for persistence. Fuel for resilience. Fuel for an optimism that endures even when confidence is missing and outcomes are uncertain. This episode explores what leadership looks like when ego is absent and responsibility is heavy. It looks at how calm decision making is formed under pressure, how humility can coexist with ambition, and how repeated success does not erase insecurity but can coexist with it in a healthy, grounded way. Rather than focusing on deal mechanics, this conversation focuses on the human side of leadership. The inner forces that keep leaders moving forward when logic says stop, when the stakes are enormous, and when clarity only emerges after action is taken. Topics discussed include: Childhood insecurity and the lasting impact of early experiences Feeling out of place and why it does not have to define who you become How insecurity can quietly fuel optimism and perseverance Gratitude, grit, and the discipline of simply doing the work Leading without ego while carrying responsibility for billions Staying grounded and calm during hostile bids and high pressure moments Willing to Win is a podcast about biotech leadership against all odds. It focuses on real decisions, inner battles, and the mindset that keeps leaders moving forward when certainty is impossible and the stakes are real. Episode 2 guest: Edwin Moses Edwin Moses has more than 30 years of Board level experience as a serial entrepreneur and value creator in over 20 European life science companies. As CEO, he built, Oxford Asymmetry International plc and Ablynx NV, led successful IPOs on the LSE, EuroNext and NASDAQ, and raised over USD500 million in equity and debt financing.  Edwin was responsible for the sales of both companies generating values of £316 million and USD4.8 billion respectively.  Edwin is currently also Chairman of Avantium NV, LabGenius Ltd and NanoSyrinx Ltd.

    42 Min.

Bewertungen und Rezensionen

5
von 5
2 Bewertungen

Info

Biotech Leaders Against All Odds Biotech leaders, founders and executives are warriors chasing cures against impossible odds. Their journeys are not only about science, but about belief, resilience, and leadership. Willing to Win is the podcast where these stories are told - the late nights, the rejections, the doubts, and the unshakable conviction that keeps them going. Each episode gives listeners an intimate look into the emotional “why” behind biotech leaders, offering inspiration, connection, and lessons in leadership and perseverance that apply far beyond biotech.